Número 1 - EII al dÃa
Número 1 - EII al dÃa
Número 1 - EII al dÃa
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Tabla III. Princip<strong>al</strong>es complicaciones de los reservorios íleo-an<strong>al</strong>es. En la columna de la izquierda datos extraídos<br />
de diversas series mundi<strong>al</strong>es; en la derecha, resultados en el Hospit<strong>al</strong> Universitario de Bellvitge (datos en %).<br />
Diversas series mundi<strong>al</strong>es<br />
Hospit<strong>al</strong> Universitario de Bellvitge<br />
Complicaciones sépticas 25 15,5<br />
Reservoritis 50 29<br />
Disfunción esfinteriana 27 24,4<br />
Disfunción sexu<strong>al</strong> 27 4,3<br />
Fracaso del reservorio 8-15 13,4<br />
BIBLIOGRAFÍA<br />
1. Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease:<br />
pharmacology and preliminary results. Mayo Clin Proc 1996; 71: 69-80.<br />
2. Schröder O, Stein J. Low dose methotrexate in inflammatory bowel disease:<br />
current status and future directions. AJG 2003; 98: 530-7.<br />
3. Paoluzi OA, Pica R, Marcheggiano A, et <strong>al</strong>. Azathioprine or methotrexate<br />
in the treatment of patients with steroid-dependent or steroid-resistant<br />
ulcerative colitis: results of an open-label study on efficacy and tolerability<br />
in inducing and maintaining remission. Aliment Pharmacol Ther 2002;<br />
16: 1751-9.<br />
4. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine<br />
or methotrexate added to prednisone induces and maintains<br />
remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol<br />
Hepatol 2000; 12: 1227-33.<br />
5. Baron TH, Truss CD, Elson CO. Low-dose or<strong>al</strong> methotrexate in refractory<br />
inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6.<br />
6. Egan LJ, Sandborn WJ, Tremaine WJ, et <strong>al</strong>. A randomized dose-response<br />
and pharmacokinetic study of methotrexate for refractory inflammatory<br />
Crohn´s disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13:<br />
1597-1604.<br />
7. Cummings JRF, Herrlinger KR, Travis SPL, et <strong>al</strong>. Or<strong>al</strong> Methotrexate in ulcerative<br />
colitis. Aliment Pharmacol Ther 2005; 21: 385-9.<br />
8. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory<br />
bowel disease. Drug Safety 2000; 23(5): 429-48.<br />
9. Newman M, Auerbach R, Feiner H, et <strong>al</strong>. The role of liver biopsies in psoriatic<br />
patients receiving long-term methotrexate treatment: improvement<br />
in liver abnorm<strong>al</strong>ities after cessation of treatment. Arch Dermatol 1989;<br />
125: 1218-24.<br />
10. VanDooren-Greebe RJ, Kuijpers AL, Mulder A, et <strong>al</strong>. Methotrexate revised:<br />
effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130:<br />
204-10.<br />
11. Oren R, Areber N Odes S, et <strong>al</strong>. Methotraxate in chronic active ulcertive<br />
colitis: a double blind, randomized, Israeli multicenter tri<strong>al</strong>. Gastroenterology<br />
1996; 110: 14416-21.<br />
12. Kozarek RA, Patterson DJ, Gelfand MD, et <strong>al</strong>. Methotrexate induces clinic<strong>al</strong><br />
and histologic<strong>al</strong> remission in patients with refractory inflammatory<br />
bowel disease. Ann Intern Med 1989; 110: 353-6.<br />
13. Delaini GG, Scaglia M, Colucci G, et <strong>al</strong>. The ileoan<strong>al</strong> pouch procedure in the<br />
long-term perspective: a critic<strong>al</strong> review. Tech Coloproctol 2005; 9: 187-92.<br />
14. Svaninger G, Nordgren S, Oresland T, et <strong>al</strong>. Incidence and characteristics<br />
of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scan<br />
J Gastroenterol 1993; 28: 695-700.<br />
15. Sánchez Santos R, de Oca J, Parés D, et <strong>al</strong>. Morbilidad y resultados funcion<strong>al</strong>es<br />
a largo plazo de los reservorios ileoan<strong>al</strong>es. Cir Esp 2002; 72:<br />
132-6.<br />
16. Meagher AP, Farouk R, Dozois RR, et <strong>al</strong>. J ile<strong>al</strong> pouch-an<strong>al</strong> anastomosis<br />
for chronic ulcerative colitis: complications and long-term outcomes in<br />
1310 patients. Br J Surg 1998; 85: 800-3.<br />
17. De Oca J, Sánchez Santos R, Martí Ragué J, et <strong>al</strong>. Anxiety and qu<strong>al</strong>ity of<br />
life <strong>al</strong>ter restorative proctocolectomy with ileoan<strong>al</strong> pouch. Colorec Dis<br />
2002; 4(S1):76.<br />
COMENTARIO<br />
E. Cabré Gelada<br />
Servicio de Aparato Digestivo. Hospit<strong>al</strong> Universitario Germans Trias i Pujol. Bad<strong>al</strong>ona. España<br />
Los artículos que preceden a este comentario son un fiel<br />
reflejo de los argumentos esgrimidos por los doctores<br />
González-Lama y de Oca, en el debate que tuvo lugar<br />
el pasado día 7 de Octubre de 2006, en el marco de la<br />
XVII Reunión Nacion<strong>al</strong> de GETECCU, que quien firma estas<br />
líneas tuvo el privilegio de moderar. Como en la inmensa<br />
mayoría de debates en los que se plantea una<br />
cuestión dicotómica (sí/no), ninguno de los contendientes<br />
30 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 6 - Nº. 1 - 2007